Approval for Endometriosis study in Ukraine obtained
Global Clinical Trials has been recently awarded to run a new project in Women’s Health. The goal of the study is to assess the efficacy and safety of the Investigational Product (IP) for the treatment of endometriosis in women of reproductive age.
On March 23rd, 2021, the State Expert Centre of MOH of Ukraine has issued approval to begin the enrollment.
April 6, 2021
Study in COVID-19 Patients to be Conducted by GCT
Global Clinical Trials has been awarded a Phase I study in COVID-19 patients for a U.S. sponsor. Proud to have 80% of the projects as repeat business, GCT is currently collaborating with the sponsor on another clinical trial in the U.S.
March 30, 2021
GCT partners with Chinese Pharma company to conduct Global Phase III trial in patients with NSCLC
GCT has been awarded the international multicenter phase III clinical trial of a tumor-starving (anti-angiogenic) therapy. The global enrollment target is 608 patients diagnosed with Non-Small Cell Lung Cancer. The first patient was randomized by GCT in the U.S. beginning of 2021.
March 29, 2021
COVID-19 Study in the U.S. Awarded to GCT
Global Clinical Trials has been selected to conduct a Phase I study in COVID-19 patients. The Investigational Medicinal Product is a nasal antiseptic formulation designed to ease the symptoms and reduce SAR COVID-19 viral load. It will be available over the counter for anyone in need.
March 11, 2021
GCT to collaborate with Greek Pharmaceutical Company in Russia
GCT was awarded a new regulatory project by a Greek Pharmaceutical company. It aims to develop a novel fixed-dose combination of the currently approved active substances doses into an immediate release film-coated tablet. The intended indication is “common cold with fever and nasal congestion”.
February 25, 2021
GCT organizes Investigators’ Meeting for medical device study in Romania
GCT started the new year with conducting an Investigators’ Meeting on behalf of the European Sponsor – NanoGun Technology (NGT). NGT is an innovative company certified by the French government in nanomaterial biotechnology. IMDENDRIM is an experimental in situ anticancer treatment of solid tumors nonresponsive to conventional therapy.
January 25, 2021
Study in Primary Mitochondrial Myopathy (PMM) Awarded
GCT has been selected to run a new project in patients diagnosed with PMM by its long-term Client. This Phase 2, multicenter, double-blind, placebo-controlled study will be managed by GCT team in Czech Republic and Hungary.
January 11, 2021
Meet our clients
All trademarks, brand names and logotypes are intellectual property of their respective owners.